Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:234 |
Name | colon adenocarcinoma |
Definition | A colon carcinoma that derives_from epithelial cells of glandular origin. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer intestinal cancer large intestine cancer colorectal cancer colon cancer colon carcinoma colon adenocarcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
PIK3CA E542K | VS-5584 | colon adenocarcinoma | sensitive | detail... |
BRAF V600E | N/A | colon adenocarcinoma | not applicable | detail... |
BRAF L597Q | Trametinib | colon adenocarcinoma | predicted - sensitive | detail... |
BRAF L597Q | Selumetinib | colon adenocarcinoma | predicted - sensitive | detail... |
BRAF L597Q | Sapitinib | colon adenocarcinoma | predicted - sensitive | detail... |
BRAF L597Q | Cetuximab + Trametinib | colon adenocarcinoma | predicted - sensitive | detail... |
BRAF V600E | Dabrafenib + Regorafenib + Trametinib | colon adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK | Alectinib | colon adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK L1319V | Alectinib | colon adenocarcinoma | predicted - resistant | detail... |
ATM Q628Pfs*7 ATM I1581Nfs*5 ATM A2843V | RP-3500 | colon adenocarcinoma | sensitive | detail... |
BRAF V600E MAP2K1 D67N | Vemurafenib | colon adenocarcinoma | resistant | detail... |
BRAF V600E MAP2K1 P124S | Vemurafenib | colon adenocarcinoma | resistant | detail... |
BRAF V600E MAP2K1 G128D | Vemurafenib | colon adenocarcinoma | resistant | detail... |
BRAF V600E MAP2K1 E203K | Vemurafenib | colon adenocarcinoma | resistant | detail... |
BRAF V600E MAP2K1 D67N | Cobimetinib | colon adenocarcinoma | resistant | detail... |
BRAF V600E MAP2K1 P124S | Cobimetinib | colon adenocarcinoma | resistant | detail... |
BRAF V600E MAP2K1 G128D | Cobimetinib | colon adenocarcinoma | resistant | detail... |
BRAF V600E MAP2K1 E203K | Cobimetinib | colon adenocarcinoma | resistant | detail... |
BRAF V600E MAP2K1 L115P | Cobimetinib | colon adenocarcinoma | resistant | detail... |
BRAF V600E MAP2K1 I99_K104del | Cobimetinib | colon adenocarcinoma | resistant | detail... |
BRAF V600E | Cetuximab + Dabrafenib + Trametinib | colon adenocarcinoma | predicted - sensitive | detail... |
BRAF V47_M438del BRAF V600E | Cetuximab + Irinotecan + Vemurafenib | colon adenocarcinoma | predicted - resistant | detail... |
BRAF K601E | Binimetinib + Cetuximab + Encorafenib | colon adenocarcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00602329 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Bevacizumab | MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer | Terminated | USA | 0 |
NCT01001377 | Phase III | Cetuximab Panitumumab | ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer | Completed | USA | SWE | SVK | ROU | POL | NLD | LVA | LTU | ITA | ISR | GBR | FRA | CZE | CAN | BGR | BEL | AUS | 12 |
NCT01103323 | Phase III | Regorafenib | Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy | Completed | USA | TUR | NLD | ITA | ISR | HUN | FRA | ESP | DEU | CHE | CAN | BRA | BEL | AUS | ARG | 4 |
NCT01206530 | Phase Ib/II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Bevacizumab Hydroxychloroquine | FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer | Completed | USA | 0 |
NCT01298570 | Phase II | Fluorouracil + Irinotecan + Leucovorin Regorafenib | Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer | Completed | USA | IRL | 0 |
NCT01442935 | Phase II | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Cetuximab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases | Completed | FRA | 0 |
NCT01471353 | Phase II | Capecitabine + Sorafenib | Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT01516216 | Phase II | Bevacizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | Study of Vitamin D in Untreated Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT01538680 | Phase III | Regorafenib | Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy | No longer available | USA | SWE | POL | NOR | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BEL | AUT | AUS | 3 |
NCT01571284 | Phase III | Aflibercept + Fluorouracil + Irinotecan + Leucovorin | Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen | Completed | USA | TUR | SWE | NOR | NLD | LBN | ITA | ISR | IRL | GBR | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BEL | 5 |
NCT01652482 | Phase II | Cetuximab Duligotuzumab Fluorouracil + Irinotecan + Leucovorin | A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer | Completed | USA | ROU | NZL | ITA | GBR | FRA | ESP | DEU | BEL | AUS | 0 |
NCT01803282 | Phase I | Andecaliximab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Carboplatin + Pemetrexed Disodium Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Carboplatin + Paclitaxel Paclitaxel Bevacizumab | Safety and Tolerability Study in Solid Tumors | Completed | USA | 0 |
NCT01814501 | Phase II | Fluorouracil + Irinotecan + Leucovorin Panitumumab | Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab | Unknown status | USA | 0 |
NCT01896856 | Phase Ib/II | Guadecitabine + Irinotecan Regorafenib | Phase I Study of SGI-110 With Irinotecan Followed by Randomized Phase II Study of SGI-110 With Irinotecan Versus Regorafenib in Previously Treated Metastatic Colorectal Cancer | Completed | USA | NLD | 0 |
NCT01910610 | Phase III | Cetuximab Irinotecan + Panitumumab Panitumumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Capecitabine + Oxaliplatin Cetuximab + Irinotecan Cetuximab + Fluorouracil + Irinotecan + Leucovorin | Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer (STRATEGIC-1) | Active, not recruiting | ISR | IRL | FRA | 0 |
NCT01939223 | Phase III | Regorafenib | COlorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo?Controlled Phase-III STudy (COAST) | Terminated | USA | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | 3 |
NCT01949194 | Phase II | Regorafenib | Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers | Unknown status | CAN | 0 |
NCT02008383 | Phase I | Cabozantinib + Panitumumab | Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT02045030 | Phase II | Aflibercept + Fluorouracil + Irinotecan + Leucovorin | Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer | Terminated | CAN | 0 |
NCT02046538 | Phase II | Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Aflibercept | Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer | Withdrawn | USA | 0 |
NCT02096354 | Phase II | Regorafenib | A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT02119676 | Phase II | Regorafenib Ruxolitinib | Study of Ruxolitinib in Colorectal Cancer Patients | Terminated | USA | ISR | GBR | FRA | ESP | DEU | AUS | 1 |
NCT02138617 | Phase II | Leucovorin Bevacizumab Irinotecan Fluorouracil | Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT02164916 | Phase II | Cetuximab + Irinotecan Cetuximab + Irinotecan + Vemurafenib | S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT02195011 | Phase II | Regorafenib | Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases | Completed | USA | 0 |
NCT02305758 | Phase II | Fluorouracil + Irinotecan + Leucovorin Bevacizumab Veliparib | Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer | Completed | 0 | |
NCT02368886 | Phase II | Clobetasol + Regorafenib | Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT02384759 | Phase II | Aflibercept + Fluorouracil + Leucovorin Fluorouracil + Leucovorin | Aflibercept +/- LV5FU2 in First Line of Non-resectalbe Metastatic Colorectal Cancers (FOLFA) | Completed | FRA | 0 |
NCT02393755 | Phase Ib/II | Capecitabine + Nintedanib | Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT02450175 | Phase I | Letrozole Everolimus | Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls | Unknown status | USA | 0 |
NCT02575508 | Phase Ib/II | Fluorouracil + Infigratinib + Irinotecan + Oxaliplatin | Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer | Withdrawn | USA | 0 |
NCT02581059 | Phase II | Regorafenib | Efficacy of Ginseng for Patients on Regorafenib | Terminated | USA | 0 |
NCT02651415 | Phase II | Perindopril + Regorafenib | Phase II Study of Perindopril and Regorafenib in mCRC | Completed | CAN | 0 |
NCT02664077 | Phase III | Regorafenib | A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer (ARGO) | Terminated | USA | 0 |
NCT02687009 | Phase I | Niclosamide | A Study of Niclosamide in Patients With Resectable Colon Cancer | Terminated | USA | 0 |
NCT02788279 | Phase III | Atezolizumab Atezolizumab + Cobimetinib Regorafenib | A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma | Completed | USA | POL | ITA | GBR | ESP | CAN | BEL | AUS | 3 |
NCT02912559 | Phase III | Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin | Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair | Active, not recruiting | USA | DEU | 1 |
NCT02934529 | Phase III | Cetuximab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Capecitabine + Fluorouracil + Leucovorin Regorafenib | Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab (AIO-KRK-0114) | Active, not recruiting | DEU | 0 |
NCT02972034 | Phase I | MK-8353 + Pembrolizumab | Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013) | Terminated | USA | CAN | 0 |
NCT02997228 | Phase III | Atezolizumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin | Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Microsatellite Instability-High Metastatic Colorectal Cancer | Recruiting | USA | 0 |
NCT03026140 | Phase II | Ipilimumab + Nivolumab Celecoxib + Ipilimumab + Nivolumab Nivolumab + Relatlimab BMS-986253 + Nivolumab | Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (NICHE) | Recruiting | NLD | 0 |
NCT03043313 | Phase II | Trastuzumab + Tucatinib Tucatinib | Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer | Completed | USA | ITA | FRA | ESP | BEL | 0 |
NCT03144804 | Phase II | Lamivudine | A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT03261947 | Phase II | Simurosertib | A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors | Completed | USA | 1 |
NCT03279289 | Phase II | Aflibercept + Fluorouracil + Irinotecan + Leucovorin Aflibercept + Fluorouracil + Leucovorin | Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen (AFEMA) | Completed | ESP | 0 |
NCT03365882 | Phase II | Cetuximab + Irinotecan Pertuzumab + Trastuzumab | S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery | Active, not recruiting | USA | 1 |
NCT03368859 | Phase II | ABT-165 + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin | A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine/Oxaliplatin and Bevacizumab | Terminated | USA | ESP | CAN | BEL | 2 |
NCT03436563 | Phase Ib/II | Bintrafusp alfa | M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability | Completed | USA | 0 |
NCT03520946 | Phase III | Ramucirumab + Trifluridine-tipiracil hydrochloride Trifluridine-tipiracil hydrochloride | RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients (RAMTAS) | Completed | DEU | 0 |
NCT03592641 | Phase II | Savolitinib | Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer | Terminated | USA | 0 |
NCT03635021 | Phase III | Fluorouracil + Irinotecan + Leucovorin + Panitumumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab | Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer (CR-SEQUENCE) | Active, not recruiting | ESP | 0 |
NCT03692429 | Phase I | Fluorouracil + Leucovorin + NKR-2 cells + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + NKR-2 cells | alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells (alloSHRINK) | Recruiting | USA | BEL | 0 |
NCT03801915 | Phase II | MVT-5873 | Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers | Completed | USA | 0 |
NCT03803553 | Phase III | Binimetinib + Cetuximab + Encorafenib Nivolumab Fluorouracil + Irinotecan + Leucovorin | Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer | Recruiting | USA | 0 |
NCT03811652 | Phase I | MEDI7247 | A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors | Completed | USA | CAN | 0 |
NCT03829462 | Phase III | Regorafenib Irinotecan + Regorafenib | Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients (NEXT-REGIRI) | Active, not recruiting | FRA | 0 |
NCT03866239 | Phase I | Atezolizumab + Obinutuzumab + RO6958688 | A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma | Terminated | USA | FRA | ESP | DNK | 0 |
NCT03867799 | Phase II | Nivolumab + Relatlimab | iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer | Active, not recruiting | GBR | 0 |
NCT03948763 | Phase I | mRNA 5671 mRNA 5671 + Pembrolizumab | A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) | Completed | USA | NZL | AUS | 4 |
NCT03992456 | Phase II | Panitumumab Regorafenib Trifluridine-tipiracil hydrochloride | Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT04017650 | Phase Ib/II | Cetuximab + Encorafenib + Nivolumab | Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT04034173 | Phase II | Fluorouracil + Irinotecan + Leucovorin + Panitumumab | Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation | Not yet recruiting | DEU | 0 |
NCT04034459 | Phase II | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC (AIO-KRK-0116) | Active, not recruiting | DEU | 0 |
NCT04044430 | Phase Ib/II | Binimetinib + Encorafenib + Nivolumab | Encorafenib, Binimetinib, and Nivolumab in Treating Patients With Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer | Terminated | USA | 0 |
NCT04109924 | Phase II | Bevacizumab + Irinotecan + Trifluridine-tipiracil hydrochloride | TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study | Active, not recruiting | USA | 0 |
NCT04126733 | Phase II | Nivolumab + Regorafenib | Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable) | Completed | USA | 0 |
NCT04158349 | Phase I | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | Intraperitoneal Oxaliplatin in Combo w IV mFOLFIRI for Peritoneal Carcinomatosis From Colorectal & Appendiceal Cancer (IPOX-FOLFIRI) | Terminated | USA | 0 |
NCT04169347 | Phase II | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Panitumumab | FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT04231526 | Phase II | Pembrolizumab | Pembrolizumab in Early Stage Colon Cancer | Withdrawn | USA | 0 |
NCT04282044 | Phase I | CRX100 | Study of CRX100 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04362839 | Phase I | Ipilimumab + Nivolumab + Regorafenib | Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT04450836 | Phase II | Regorafenib + Trifluridine-tipiracil hydrochloride | Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer (SOREGATT) | Active, not recruiting | FRA | BEL | 0 |
NCT04479436 | Phase II | Patritumab deruxtecan | A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer | Terminated | USA | POL | ITA | GBR | FRA | ESP | BEL | 1 |
NCT04495621 | Phase Ib/II | Cetuximab + MEN1611 | MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01) (C-PRECISE-01) | Completed | USA | POL | NLD | ITA | FRA | ESP | DEU | 0 |
NCT04554836 | Phase II | Cetuximab + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin | MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab | Active, not recruiting | DEU | 0 |
NCT04579757 | Phase Ib/II | Surufatinib + Tislelizumab | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT04599140 | Phase Ib/II | Nivolumab + SX-682 SX-682 | SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial | Recruiting | USA | 0 |
NCT04607668 | Phase III | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Trilaciclib | Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC): (PRESERVE1) | Terminated | USA | POL | ITA | HUN | GBR | ESP | 2 |
NCT04616183 | Phase Ib/II | Abemaciclib + Cetuximab + LY3214996 Cetuximab + LY3214996 | LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT04689347 | Phase I | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Temozolomide | 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer. | Unknown status | ITA | 0 |
NCT04737187 | Phase III | Bevacizumab + Trifluridine-tipiracil hydrochloride Trifluridine-tipiracil hydrochloride | Phase III Study of Trifluridine/Tipiracil in Combination With Bevacizumab vs Trifluridine/Tipiracil Single Agent in Patients With Refractory Metastatic Colorectal Cancer (SUNLIGHT) | Completed | USA | POL | ITA | HUN | FRA | ESP | DNK | DEU | BRA | BEL | AUT | 3 |
NCT04826003 | Phase Ib/II | Obinutuzumab + RO6958688 + RO7122290 | Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment | Active, not recruiting | NLD | GBR | ESP | DNK | 1 |
NCT04929223 | Phase I | Bevacizumab + Inavolisib Cetuximab + Inavolisib | A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (Intrinsic) | Active, not recruiting | USA | POL | ITA | GBR | ESP | DNK | DEU | CAN | AUS | 2 |
NCT04991948 | Phase I | Fluorouracil + Leucovorin + NKR-2 cells + Oxaliplatin + Pembrolizumab | Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer | Recruiting | USA | BEL | 0 |
NCT05007132 | Phase II | Bevacizumab + Trifluridine-tipiracil hydrochloride Panitumumab + Trifluridine-tipiracil hydrochloride | Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer | Recruiting | DEU | 0 |
NCT05062889 | Phase II | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Capecitabine + Oxaliplatin Trifluridine-tipiracil hydrochloride Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib | Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients (ERASE-CRC) | Recruiting | ITA | 0 |
NCT05118724 | Phase II | Atezolizumab | Atezolizumab in Patients With MSI-h/MMR-D Stage III Colorectal Cancer Ineligible for Oxaliplatin (ANTONIO) | Recruiting | DEU | 0 |
NCT05130060 | Phase I | PolyPEPI1018 + Trifluridine-tipiracil hydrochloride | A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT05178576 | Phase II | XOMA 052 | A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy | Withdrawn | USA | 0 |
NCT05197322 | Phase II | Pembrolizumab | NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer (NEOPRISM-CRC) | Recruiting | GBR | 0 |
NCT05205330 | Phase Ib/II | Balstilimab + CR6086 | CR6086/AGEN2034 Combination in Stage IV pMMR - MSS CRC, and Other Metastatic GI Cancers | Recruiting | ITA | 0 |
NCT05300048 | Phase I | Serabelisib Nab-paclitaxel + Serabelisib | Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations | Active, not recruiting | USA | 0 |
NCT05308446 | Phase II | Cetuximab + Encorafenib Cetuximab + Encorafenib + Nivolumab | Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation | Active, not recruiting | USA | 1 |
NCT05322590 | Phase Ib/II | BXQ-350 | BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma (ASIST) | Recruiting | USA | 0 |
NCT05356897 | Phase II | Trastuzumab + Trifluridine-tipiracil hydrochloride + Tucatinib | Tucatinib Combined With Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study | Withdrawn | USA | 0 |
NCT05379595 | Phase Ib/II | Amivantamab-vmjw Amivantamab-vmjw + Fluorouracil + Irinotecan + Leucovorin Amivantamab-vmjw + Fluorouracil + Leucovorin + Oxaliplatin | A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer (OrigAMI-1) | Recruiting | USA | ITA | ESP | DEU | CAN | BEL | 5 |
NCT05400122 | Phase I | Aldesleukin + Vactosertib Cyclophosphamide + Fludarabine | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer | Recruiting | USA | 0 |
NCT05425940 | Phase III | Atezolizumab + XL092 Regorafenib | Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303) | Active, not recruiting | USA | POL | NZL | HUN | GBR | FRA | ESP | DEU | BEL | AUS | 6 |
NCT05453825 | Phase II | Irinotecan + Navicixizumab Navicixizumab Navicixizumab + Paclitaxel | A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05510895 | Phase II | Binimetinib + Cetuximab + Encorafenib | Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer (NeoBRAF) | Recruiting | DEU | 0 |
NCT05571293 | Phase II | Balstilimab + Botensilimab | Combination Immunotherapy in Colorectal Cancer (NEST-1) | Recruiting | USA | 0 |
NCT05627635 | Phase Ib/II | Balstilimab + Bevacizumab + Botensilimab + Fluorouracil + Leucovorin + Oxaliplatin | FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer | Recruiting | USA | 0 |
NCT05672316 | Phase Ib/II | Balstilimab + Botensilimab + Regorafenib | Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy | Active, not recruiting | USA | 0 |
NCT05706779 | Phase II | Cetuximab + Encorafenib | Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer (NEORAF) | Recruiting | FRA | 0 |
NCT05710406 | Phase II | Cetuximab + Encorafenib | Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer | Recruiting | USA | 0 |
NCT05722327 | Phase I | Adagrasib + Cetuximab + Irinotecan | Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer | Recruiting | USA | 0 |
NCT05725200 | Phase II | Dasatinib Palbociclib Gemcitabine Trastuzumab Cetuximab Pertuzumab Panobinostat Alectinib Venetoclax Larotrectinib Encorafenib Everolimus Idelalisib Crizotinib Pembrolizumab Methotrexate Talazoparib | Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer (EVIDENT) | Recruiting | NOR | 0 |
NCT05824559 | Phase I | Bevacizumab + ME-344 | ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer | Terminated | USA | 0 |
NCT05870800 | Phase II | Atezolizumab + Capecitabine + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin Capecitabine + Oxaliplatin | Neoadjuvant Chemoimmunotherapy for Resectable Non-Metastatic Proficient Mismatch Repair (PMMR) Colon Cancer | Not yet recruiting | USA | 0 |
NCT05954871 | Phase I | Cetuximab + GDC-1971 GDC-1971 + Osimertinib | Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer | Active, not recruiting | USA | CAN | AUS | 1 |
NCT05961709 | Phase II | Cemiplimab | The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer | Recruiting | USA | 0 |
NCT05985954 | Phase I | Cetuximab + Encorafenib + Ulixertinib Cetuximab + Ulixertinib | Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy | Recruiting | USA | 0 |
NCT05999812 | Phase II | Atezolizumab + Bevacizumab + Tretinoin | Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer | Recruiting | USA | 0 |
NCT06011772 | Phase I | CIMAvax-EGF Bevacizumab + Cetuximab + CIMAvax-EGF + Leucovorin Bevacizumab + CIMAvax-EGF + Fluorouracil + Leucovorin + Oxaliplatin Cetuximab + CIMAvax-EGF + Fluorouracil + Oxaliplatin Cetuximab + CIMAvax-EGF + Fluorouracil + Irinotecan + Leucovorin | EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer | Recruiting | USA | 0 |
NCT06055439 | Phase Ib/II | CHM-2101 CAR-T cells | A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy | Recruiting | USA | 0 |
NCT06225843 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin + Sotevtamab | Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis (EGIA-003) | Recruiting | CAN | 0 |
NCT06567782 | Phase II | Capecitabine + Dostarlimab-gxly + Oxaliplatin Capecitabine + Oxaliplatin | A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer (AZUR-4) | Not yet recruiting | GBR | ESP | BEL | 0 |
NCT06575725 | Phase II | Balstilimab + Botensilimab + Regorafenib Balstilimab + Botensilimab | Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer | Withdrawn | 0 | |
NCT06617858 | Phase II | AMB-05X | Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment | Not yet recruiting | USA | 0 |
NCT06634875 | Phase II | Isunakinra | Isunakinra Alone and in Combination with Pembrolizumab in Patients with Colorectal Cancer (MSS) | Not yet recruiting | USA | 0 |
NCT06646445 | Phase II | Pembrolizumab Capecitabine + Oxaliplatin Capecitabine Fluorouracil Fluorouracil + Oxaliplatin | Neoadjuvant Pembrolizumab with a Watch-and-wait Strategy for Patients with DMMR/MSI-H Localized Colon Cancer: GERCOR G-109 PRODIGE 84 PREMICES Phase II Trial (PREMICES) | Not yet recruiting | FRA | 0 |
NCT06692959 | Phase II | IMU-201 | A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer (Neo-POLEM) | Not yet recruiting | GBR | 0 |